Biotech Values

[drbio45]

The market cap of over 2 billions seems very high

As I have said previously the LAR version I believe is having problems perhaps because of nausea and immunogenicity.

The exanitide will probably get approved but has shown antibody reactions which in these short studies haven't seemed to cause a problem but if someone is using the drug for a couple of years I would be concerned.

I don't think the drug will be a huge seller because of the two shots a day situation. Either Conjuchem once or twice a week will be better if it works out that way in the july data